Now that the PrEP trial drug has been procured, we're well on the way to protecting over 10,000 people at risk of HIV.'
Nüüd, mil PrEP-i kliinilise katse ravim on hangitud, oleme teel sinnapoole, et kaitsta rohkem kui 10 000 inimest, kellel on oht HIV-sse nakatuda.